This is the fourth publication on the administration of a microdose of LSD (5, 10, or 20µg). The double-blind, placebo-controlled study (n=24) found enhanced attention, slower information processing, more positive mood, and increased anxiety and confusion. Again, the results are small and ambiguous.
Abstract of Mood and cognition after administration of low LSD doses in healthy volunteers
“There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to a specific dosing schedule, anecdotally enhances mood and performance. Nonetheless, controlled research on the efficacy of microdosing is scarce. The main objective of the present dose-finding study was to determine the minimal dose of LSD needed to affect mood and cognition. A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.”
Authors: Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding, Johannes G. Ramaekers & Kim P. C. Kuypers
Notes
This paper uses the same participants as Holze et al. (2020), Hutten et al. (2020), and Ramaekers et al. (2020). The other studies respectively looked at pharmacodynamics and felt effect (only really at 20 µg), blood plasma levels (ambiguous results), and increased pain tolerance.
This study is quite similar to Yanakieva et al. (2019), which found only small effects on mood (more vigour, lower rating of positive images).
The study is supported in part by the Beckley Foundation.
It was (lazily) reported on in Futurism (October 2020).
Although the conclusions presented in the abstract are valid. Please do consult Figure 1 in the paper to see how small and relatively ‘random’ these results are (i.e. noise). Also:
“Binomial tests indicated that the proportion of observations containing fewer attentional lapses after administration of 5 and 20 mcg LSD was respectively 76% ( p < 0.01) and 74% ( p < 0.01), while this was 38% ( p = 0.19) after 10 mcg LS.” (this is represented in the top-left bar graph in figure 1)
The same can be said of Table 3, which displays mood and cognition scores that move only ever so slightly.
Summary of Mood and cognition after administration of low LSD doses in healthy volunteers
Hutten and colleagues begin by discussing the growing interest in microdosing with psychedelics such as lysergic acid diethylamide (LSD). They explain that microdosing involves taking about one-tenth of a regular psychedelic dose according to a specific schedule, with the aim of enhancing mood and performance without causing significant alterations in consciousness. The authors note that while there is increasing popular interest in microdosing, controlled research on its efficacy is scarce.
The researchers highlight that clinical studies have demonstrated acute changes in consciousness after a single full psychedelic dose of LSD (100-200 μg) in healthy volunteers. These changes include perceptual distortions, increased blissful state, enhanced insightfulness, and improved mental wellbeing. However, less is known about the effects of very low doses of LSD.
Find this paper
https://doi.org/10.1016/j.euroneuro.2020.10.002
Open Access | Google Scholar | Backup | 🕊
Cite this paper (APA)
Hutten, N. R., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., ... & Kuypers, K. P. (2020). Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. European Neuropsychopharmacology, 41, 81-91.
Study details
Compounds studied
LSD
Topics studied
Microdosing
Study characteristics
Original Re-analysis
Placebo-Controlled
Double-Blind
Within-Subject
Randomized
Participants
24
Humans
Authors
Authors associated with this publication with profiles on Blossom
Natasha MasonNatasha Mason is interested in elucidating the neurobiological and cognitive mechanisms of (psychedelic) drugs by utilizing multimodal study designs, with a particular focus on substances that may hold therapeutic value.
Matthias Liechti
Matthias Emanuel Liechti is the research group leader at the Liechti Lab at the University of Basel.
Amanda Feilding
Amanda is the Founder and Director of the Beckley Foundation. She's called the 'hidden hand' behind the renaissance of psychedelic science, and her contribution to global drug policy reform has also been pivotal and widely acknowledged.
Johannes Ramaekers
Johannes Ramaekers is a professor at Maastricht University his work focuses on behavioral toxicology of drugs and combines methods from psychopharmacology, forensic toxicology and neuroscience to determine drug-induced changes in human performance. Some of this research is done with DMT.
Kim Kuypers
Kim Kuypers is a researcher at Maastricht University. Her work is concerned with understanding the neurobiology underlying flexible cognition, empathy, and well-being. One of the main ways she does is with the use of psychedelics.
Institutes
Institutes associated with this publication
Beckley FoundationThe Beckley Foundation is one of the leading voices that has spurred the scientific renaissance of psychedelics research. Led by Amanda Fielding, the NGO funds research and engages with politicians.
Maastricht University
Maastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.
Compound Details
The psychedelics given at which dose and how many times
LSD 5 - 20μg | 1x
Linked Research Papers
Notable research papers that build on or are influenced by this paper
Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide microdoses in healthy participantsThis is the third publication of a four-part study. The double-blind, placebo-controlled study (n=23) found that 10 µg of LSD (vs 5µg) produced psychedelic (psychotropic) effects (even more so at 20µg). The peak effects were at 2.5 hours and ended at 5 hours.
Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers
This is the second publication of a four-part study. It was found that a microdose (20µg) of LSD increased neuroplasticity as measured by brain-derived neurotrophic factor (BDNF) levels at 6 hours (n=24). The results are, however, ambiguous and not present at all values/times.
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers
This is the first of a four-part study (n=24) exploring the effects of a microdose of LSD (5-20µg) on a range of measures, including mood, cognition, empathy, creativity, and physiological parameters. This part of the study found that LSD increased the pain tolerance of participants.